De Chao Yu
Vorstandsvorsitzender bei INNOVENT BIOLOGICS, INC.
Vermögen: 530 Mio $ am 30.04.2024
Profil
De Chao Yu ist Gründer von Innovent Biologics, Inc. und Chengdu Kanghong Pharmaceutical Group Co., Ltd. und bekleidet die Position des Chairman & Chief Executive Officer bei Innovent Biologics, Inc. sowie den Vorsitz der Chinese Antibody Society. Er ist außerdem im Vorstand der Babytree Group und der Cheerwin Group Ltd. und Professor an der Sichuan University. De Chao Yu war zuvor President & Chief Executive Officer bei Chengdu Kanghong Pharmaceutical Group Co., Ltd, Vice President-Research & Development von Applied Genetic Technologies Corp., Vice President-Research & Development bei Applied Genetics, Inc., President & Chief Executive Officer für Kanghong Sagent Chengdu Pharmaceutical Corp. Ltd, Vice President-Research & Development bei Calyon North America, Inc. und Vice President bei Calydon, Inc. sowie Managing Director bei China Medicinal Biotech Association. Er erhielt einen Doktortitel von der Chinesischen Akademie der Wissenschaften.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
INNOVENT BIOLOGICS, INC.
6,68% | 03.05.2024 | 108 338 915 ( 6,68% ) | 530 Mio $ | 30.04.2024 |
Aktive Positionen von De Chao Yu
| Unternehmen | Position | Beginn |
|---|---|---|
| INNOVENT BIOLOGICS, INC. | Vorstandsvorsitzender | 28.04.2011 |
| Sichuan University | Corporate Officer/Principal | 01.01.2008 |
| Chinese Antibody Society | Vorsitzender | 01.01.2017 |
Ehemalige bekannte Positionen von De Chao Yu
| Unternehmen | Position | Ende |
|---|---|---|
| BABYTREE GROUP | Direktor/Vorstandsmitglied | 10.05.2023 |
| CHEERWIN GROUP LIMITED | Direktor/Vorstandsmitglied | 14.10.2022 |
| China Medicinal Biotech Association | Corporate Officer/Principal | 01.01.2019 |
| PHARMABLOCK SCIENCES (NANJING), INC. | Direktor/Vorstandsmitglied | 01.01.2018 |
| CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD | Vorstandsvorsitzender | 01.01.2011 |
Ausbildung von De Chao Yu
| Chinese Academy of Sciences | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| INNOVENT BIOLOGICS, INC. | Health Technology |
| CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD | Health Technology |
| PHARMABLOCK SCIENCES (NANJING), INC. | Commercial Services |
| BABYTREE GROUP | Commercial Services |
| CHEERWIN GROUP LIMITED | Process Industries |
| Private Unternehmen | 7 |
|---|---|
Kanghong Sagent Chengdu Pharmaceutical Corp. Ltd.
 Kanghong Sagent Chengdu Pharmaceutical Corp. Ltd. Pharmaceuticals: MajorHealth Technology Part of Ellimist Singapore Pte Ltd., Kanghong Sagent Chengdu Pharmaceutical Corp. Ltd. is a pharmaceutical company that manufactures and supplies pharmaceutical products. The company is based in Chengdu, China. Kanghong Sagent Chengdu Pharmaceutical Corp. was acquired by Sagent Pharmaceuticals, Inc., part of Ellimist Singapore Pte Ltd. from February 28, 2023 on June 04, 2013 for $4.06 million. The Chinese company was founded in 2006. | Health Technology |
| Applied Genetics, Inc. | |
Calyon North America, Inc.
 Calyon North America, Inc. Regional BanksFinance Part of SAS Rue la Boétie, Calyon North America, Inc. is a company based in New York, NY. | Finance |
Beacon Therapeutics (USA), Inc.
 Beacon Therapeutics (USA), Inc. Pharmaceuticals: GenericHealth Technology Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the usage of a gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The firm also focuses on conducting clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL. | Health Technology |
| China Medicinal Biotech Association | |
Calydon, Inc.
 Calydon, Inc. Medical SpecialtiesHealth Technology Part of ANI Pharmaceuticals, Inc., Calydon, Inc. develops therapeutic products for cancer. The company is based in Sunnyvale, CA. Calydon was acquired by Cell Genesys, Inc. on September 05, 2001 for $17.68 million. | Health Technology |
| Chinese Antibody Society |
